** Shares of Intellia Therapeutics down 4.2% at $11.52 premarket
** NTLA on Thursday announced plans to discontinue its early-stage therapy, NTLA-3001, for a type of lung disease
** It also plans to cut workforce by about 27% this year
** Company plans to refocus resources on two of its late-stage therapies — NTLA-2002 and nex-z — and prepare for their commercial launch
** At least three brokerages cut their PT on NTLA's stock following the company's announcement
** BMO Capital analysts say investors may question the timing of NTLA's decision since dosing in the early-stage trial of NTLA-3001 in H2 2024
** Discontinuing NTLA-3001 "is the right decision and alleviates NTLA's financing overhang" - BMO Capital
** NTLA says it ended 2024 with about $862 million in cash and equivalents; cash balance and expected cost savings to provide cash runway into H1 2027
** Shares fell ~62% in 2024
(Reporting by Bhanvi Satija in Bengaluru)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.